101421-62-9 Usage
Uses
Used in Pharmaceutical Industry:
2-BROMO-3,4-DIMETHYL-1-NITROBENZENE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs and medications, contributing to advancements in healthcare and medicine.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 2-BROMO-3,4-DIMETHYL-1-NITROBENZENE serves as an essential intermediate for the synthesis of a wide range of organic compounds. Its versatility in chemical reactions enables the creation of diverse molecules with various applications.
Used as a Research Chemical:
2-BROMO-3,4-DIMETHYL-1-NITROBENZENE is utilized as a research chemical, providing scientists and researchers with a valuable tool for studying chemical reactions, properties, and mechanisms. Its use in research contributes to the expansion of knowledge in the field of chemistry and the development of new technologies and applications.
Used in Dyes and Pigments Production:
2-BROMO-3,4-DIMETHYL-1-NITROBENZENE is employed in the production of dyes and pigments, where its chemical properties contribute to the creation of vibrant colors and stable compounds. Its use in this industry enhances the quality and variety of dyes and pigments available for various applications, including textiles, plastics, and printing inks.
Check Digit Verification of cas no
The CAS Registry Mumber 101421-62-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,4,2 and 1 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 101421-62:
(8*1)+(7*0)+(6*1)+(5*4)+(4*2)+(3*1)+(2*6)+(1*2)=59
59 % 10 = 9
So 101421-62-9 is a valid CAS Registry Number.
101421-62-9Relevant articles and documents
KRAS G12D INHIBITORS
-
Paragraph 01556, (2021/03/05)
The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER
-
Page/Page column 106, (2017/10/11)
The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.